Skip to main content
Fig. 5 | Chinese Medicine

Fig. 5

From: Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro

Fig. 5

Effects of LS on the expression levels of inflammatory mediators and the expression of the key proteins related to the NF-κB/MAPK signaling pathway in SARS-CoV-2-infected mice. A The mRNA expression of the IFN-α, IFN-γ, MCP-1 and IP-10 in the lung of the infected mice were detected by RT-qPCR analysis at the fifth d.p.i.; B The expression of the key proteins related to the NF-κB/MAPK signaling pathway was examined by western blotting; C The expression of phosphorylation of nuclear translocation of NF-κB p65 was determined by immunohistochemistry at the fifth d.p.i. Scale bar = 400 µm. a mock infected mice treated with PBS (normal control, NC); b SARS-CoV-2-infected mice treated with PBS (viral control, Virus); c SARS-CoV-2-infected mice treated with remdesivir; d–f SARS-CoV-2-infected mice treated with LS (160, 80 and 40 mg/kg). *P < 0.05; **P < 0.01; ***P < 0.001, compared with viral control

Back to article page